Author details

Full Name

Barton F Haynes

Affiliation

ORCID

Career Start Year

1973

Papers

728

H Index

137

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35547855	Disease diagnostics using machine learning of immune receptors.	bioRxiv	2024
37546738	Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.	bioRxiv	2023
35962033	Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.	Nature Reviews Immunology	2023
38036525	Engineered immunogens to elicit antibodies against conserved coronavirus epitopes.	Nat Commun	2023
37751363	Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development.		2023
36909627	Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes.	bioRxiv	2023
36961989	COVID-19 Diagnosis and SARS-CoV-2 Strain Identification by a Rapid, Multiplexed, Point-of-Care Antibody Microarray.	Anal Chem	2023
36708513	Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor.	Cell Rep	2023
37260077	ARMADiLLO: a web server for analyzing antibody mutation probabilities.		2023
37196027	Identification of CDRH3 loops in the B cell receptor repertoire that can be engaged by candidate immunogens.		2023
36633409	Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield.		2023
36629414	A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.	mBio	2023
37188681	Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage.		2023
36859597	Author Correction: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.		2023
37044090	Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.	Cell Rep Med	2023
36787249	Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.		2023
34871810	Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials.		2022
36175869	Single-cell analysis of immune cell transcriptome during HIV-1 infection and therapy.	BMC Immunology	2022
35907918	Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1.	NPJ Vaccines	2022
36302951	Expression of membrane Hsp90 is a molecular signature of T cell activation.	Scientific Reports	2022
35951767	An antibody from single human V<sub>H</sub>-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion.	Sci Immunol	2022
36274085	Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.	Nat Commun	2022
35732171	Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike.	Cell Reports	2022
35615712	Erratum: Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.	Molecular Therapy - Methods and Clinical Development	2022
35294883	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice.	Cell Reports	2022
34730393	Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.	Journal of Virology	2022
34903878	Author Correction: SARS-CoV-2 and HIV-1 - A Tale of Two Vaccines.	Nature Reviews Immunology	2022
35118474	Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine.	bioRxiv	2022
35118469	Structural diversity of the SARS-CoV-2 Omicron spike.		2022
34428080	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment.	Annual Review of Medicine	2022
34806332	Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.	Journal of the International AIDS Society	2021
34242577	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.	Cell	2021
34019795	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.	Cell	2021
33971664	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.	Nature	2021
33705729	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.		2021
34289384	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.	Cell Rep	2021
33688652	Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates.		2021
33532765	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.	bioRxiv	2021
33532764	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.		2021
34056628	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.	Cell Rep Med	2021
34004174	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells.	Cell Reports	2021
34272508	SARS-CoV-2 and HIV-1 - a tale of two vaccines.	Nature Reviews Immunology	2021
33948590	A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice.	bioRxiv	2021
33619494	SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys.	bioRxiv	2021
33837212	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.	npj Vaccines	2021
34262096	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth.	Scientific Reports	2021
33442694	The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates.	bioRxiv	2021
33824213	Erratum for Tolbert et al., "Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial".	mBio	2021
33763653	Protein/AS01 vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors.	Cell Reports Medicine	2021
34086838	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.	PLoS Pathogens	2021